Citius Pharmaceuticals (NASDAQ:CTXR) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Citius Pharmaceuticals (NASDAQ:CTXR - Free Report) in a report released on Tuesday,Benzinga reports. HC Wainwright currently has a $4.00 price target on the stock.

Separately, EF Hutton Acquisition Co. I upgraded shares of Citius Pharmaceuticals to a "strong-buy" rating in a report on Monday, July 15th.

Citius Pharmaceuticals Stock Up 4.9 %

Shares of NASDAQ CTXR traded up $0.02 during midday trading on Tuesday, hitting $0.47. The company had a trading volume of 2,308,747 shares, compared to its average volume of 1,433,909. The firm has a market capitalization of $85.18 million, a price-to-earnings ratio of -1.87 and a beta of 1.66. The business has a 50-day simple moving average of $0.45 and a two-hundred day simple moving average of $0.61. Citius Pharmaceuticals has a twelve month low of $0.31 and a twelve month high of $1.07.

Citius Pharmaceuticals (NASDAQ:CTXR - Get Free Report) last posted its earnings results on Monday, August 12th. The company reported ($0.06) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.01). On average, equities analysts forecast that Citius Pharmaceuticals will post -0.21 EPS for the current year.

Institutional Investors Weigh In On Citius Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in CTXR. Arkadios Wealth Advisors grew its position in Citius Pharmaceuticals by 33.3% in the third quarter. Arkadios Wealth Advisors now owns 200,000 shares of the company's stock valued at $100,000 after acquiring an additional 50,000 shares during the last quarter. Wealth Advisory Solutions LLC grew its stake in Citius Pharmaceuticals by 33.1% in the 3rd quarter. Wealth Advisory Solutions LLC now owns 201,000 shares of the company's stock valued at $101,000 after purchasing an additional 50,000 shares during the period. Point72 DIFC Ltd bought a new position in Citius Pharmaceuticals in the 2nd quarter valued at $29,000. Cubist Systematic Strategies LLC bought a new position in shares of Citius Pharmaceuticals during the 2nd quarter worth $69,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Citius Pharmaceuticals during the 2nd quarter worth $118,000. Institutional investors own 16.88% of the company's stock.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.